236 related articles for article (PubMed ID: 34167473)
1. Low continuation of antipsychotic therapy in Parkinson disease - intolerance, ineffectiveness, or inertia?
Pham Nguyen TP; Abraham DS; Thibault D; Weintraub D; Willis AW
BMC Neurol; 2021 Jun; 21(1):240. PubMed ID: 34167473
[TBL] [Abstract][Full Text] [Related]
2. Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis.
Moisan J; Grégoire JP
Clin Ther; 2010; 32 Suppl 1():S21-31. PubMed ID: 20152549
[TBL] [Abstract][Full Text] [Related]
3. Atypical antipsychotic use and mortality risk in Parkinson disease.
Pham Nguyen TP; Thibault D; Hamedani AG; Weintraub D; Willis AW
Parkinsonism Relat Disord; 2022 Oct; 103():17-22. PubMed ID: 36027858
[TBL] [Abstract][Full Text] [Related]
4. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
[TBL] [Abstract][Full Text] [Related]
5. Mortality in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study.
Layton JB; Forns J; McQuay LJ; Danysh HE; Dempsey C; Anthony MS; Turner ME
Drug Saf; 2023 Feb; 46(2):195-208. PubMed ID: 36517664
[TBL] [Abstract][Full Text] [Related]
6. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
7. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
8. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
9. Comparing adherence to and persistence with antipsychotic therapy among patients with bipolar disorder.
Hassan M; Madhavan SS; Kalsekar ID; Makela EH; Rajagopalan K; Islam S; Kavookjian J; Miller LA
Ann Pharmacother; 2007 Nov; 41(11):1812-8. PubMed ID: 17925501
[TBL] [Abstract][Full Text] [Related]
10. Clearing the Fog: A Review of Antipsychotics for Parkinson's-Related Hallucinations: A Focus on Pimavanserin, Quetiapine and Clozapine.
Abdul-Rahman T; Herrera-Calderón RE; Aderinto N; Kundu M; Wireko AA; Adebusoye FT; Ekerin O; Lawal L; Mykolaivna NI; Alexiou A; Almashjary MN; Perveen A; Ashraf GM
J Integr Neurosci; 2024 Apr; 23(4):80. PubMed ID: 38682215
[TBL] [Abstract][Full Text] [Related]
11. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
12. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
[TBL] [Abstract][Full Text] [Related]
13. Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia.
Kreyenbuhl J; Slade EP; Medoff DR; Brown CH; Ehrenreich B; Afful J; Dixon LB
Schizophr Res; 2011 Sep; 131(1-3):127-32. PubMed ID: 21576008
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis.
Brown JD; Cicali B; Henriksen C; Malaty I; Okun MS; Armstrong MJ
J Manag Care Spec Pharm; 2021 Jun; 27(6):785-790. PubMed ID: 34057395
[No Abstract] [Full Text] [Related]
15. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease.
Friedman JH; Factor SA
Mov Disord; 2000 Mar; 15(2):201-11. PubMed ID: 10752567
[TBL] [Abstract][Full Text] [Related]
16. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
17. Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes.
Park Y; Hernandez-Diaz S; Bateman BT; Cohen JM; Desai RJ; Patorno E; Glynn RJ; Cohen LS; Mogun H; Huybrechts KF
Am J Psychiatry; 2018 Jun; 175(6):564-574. PubMed ID: 29730938
[TBL] [Abstract][Full Text] [Related]
18. Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: a retrospective claims database analysis.
Kim E; Maclean R; Ammerman D; Jing Y; Pikalov A; You M; Van-Tran Q; L'Italien G
Clin Ther; 2009 Apr; 31(4):836-48. PubMed ID: 19446157
[TBL] [Abstract][Full Text] [Related]
19. Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies.
Horn S; Richardson H; Xie SX; Weintraub D; Dahodwala N
Parkinsonism Relat Disord; 2019 Dec; 69():119-124. PubMed ID: 31751863
[TBL] [Abstract][Full Text] [Related]
20. Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis.
Weintraub D; Chen P; Ignacio RV; Mamikonyan E; Kales HC
Arch Neurol; 2011 Jul; 68(7):899-904. PubMed ID: 21747029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
